December 31, 2014
Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (EST) on Wednesday, Feb. 11, 2015. Chief Executive Officer Juan Ramón Alaix and Executive Vice President and Chief Financial Officer Paul Herendeen will review fourth quarter and full year 2014 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. Information on accessing and pre-registering for the webcast is available beginning today. A replay of the webcast will be archived and made available on Feb. 11, 2015. About Zoetis Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and
...
December 17, 2014
The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a first quarter 2015 dividend payable to holders of the company’s common stock of $0.083 per share, an increase of 15% from the quarterly dividend rate paid in 2014. The dividend is to be paid on Tuesday, Mar. 3, 2015, to holders of record on Thursday, Jan. 22, 2015. “In 2014, we continued to demonstrate the strength of our business model and deliver our long-term value proposition, including returning capital to our shareholders through our quarterly dividends and recently announced share repurchase program,” said Zoetis Chief Executive Officer Juan Ramón Alaix. “With the Board’s approval, I am pleased to announce we are increasing our dividend by 15% as we head into 2015 and continuing our commitment to effective and efficient use of our cash.” About Zoetis Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in
...
December 17, 2014
Zoetis Inc. (NYSE:ZTS) will participate in the 33 rd Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 14, in San Francisco, Calif. Juan Ramón Alaix, Chief Executive Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 1:00 p.m. EST (10:00 a.m. PST). Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations. A replay of the presentation will also be available. About Zoetis Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. In 2013, the company generated annual revenue of $4.6 billion. With approximately 9,800
...
December 2, 2014
Zoetis Inc. (NYSE:ZTS) will participate in the Bank of America Merrill Lynch Animal & Dental Health Summit on Thursday, Dec. 11, in Boston, Mass. Paul Herendeen, Executive Vice President and Chief Financial Officer, and Clint Lewis, Executive Vice President and President, U.S. Operations, will represent the company and respond to questions from analysts. They are scheduled to present at 12:30 p.m. EST. The meeting is not scheduled to be webcast. About Zoetis Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. In 2013, the company generated annual revenue of $4.6 billion. With approximately 9,800 employees worldwide at the beginning of 2014, Zoetis has a local presence in
...
November 18, 2014
Highlights Attractive Investment Opportunity in Animal Health Industry Describes Zoetis' Competitive Advantage and Market Leadership Position Announces Full-Year 2015 Guidance of $1.61 to $1.68 for Adjusted Diluted Earnings Per Share 1 and Longer Term Financial Goals Through 2017 Zoetis Inc. (NYSE:ZTS), the world’s leading animal health company, today hosted its first-ever Investor Day, discussing with investors and analysts the company’s leadership position in the animal health industry and the strategy and initiatives underway that will drive growth and create value for shareholders. The company also provided full-year 2015 financial guidance and outlined its longer term financial goals through 2017. “Zoetis has become the world leader in the $23 billion market for animal health medicines and vaccines based on our unique combination of capabilities, our diverse portfolio of more than 300 product lines, our global presence in 120 countries and critical investments that we have made
...
November 18, 2014
Zoetis Inc. (NYSE: ZTS), the world’s leading animal health company, today announced that its Board of Directors has authorized a $500 million share repurchase program as part of its capital allocation plans. The shares are expected to be repurchased at the discretion of management, depending on market conditions and business needs. The authorization allows for repurchases to be conducted through open market or privately negotiated transactions or otherwise. “A share repurchase program is an important tool for managing our allocation of capital, and it gives us additional flexibility to return capital to shareholders when it is not needed in the business,” said Paul Herendeen, Executive Vice President and Chief Financial Officer of Zoetis. “We remain focused on investing capital internally to help grow the business; completing complementary business development activities that can generate additional value; and returning capital to shareholders as part of our total value proposition.”
...
November 14, 2014
Zoetis Inc. (NYSE: ZTS) today announced that its Board of Directors has adopted a one-year shareholder rights plan (the “Plan”) and declared a dividend distribution of one preferred share purchase right (a “Right”) for each outstanding share of the Company’s common stock. The Plan will automatically expire on November 16, 2015, unless the Rights are earlier redeemed, exchanged or terminated. The Plan is intended to protect shareholders and the Company from any attempt to take control of the Company that the Board of Directors determines is not in the best interest of shareholders and does not reflect the Company’s unique industry position and long term value. It is also designed to provide the Board sufficient time to make fully informed decisions in response to any open market or other accumulation of shares. The Plan is not intended to prevent an offer to acquire the Company or any other business combination the Board may approve and, as such, may be amended, redeemed or terminated
...
November 5, 2014
Zoetis Inc. (NYSE:ZTS) will participate in the Piper Jaffray 26th Annual Healthcare Conference on Tuesday, Dec. 2, in New York, N.Y. Paul Herendeen, Executive Vice President and Chief Financial Officer, and Dr. Catherine Knupp, Executive Vice President and President, Research and Development, will represent the company and respond to questions from analysts. They are scheduled to present at 8:30 a.m. EST. Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations. A replay of the presentation will also be available. About Zoetis Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services.
...
November 4, 2014
Third Quarter 2014 Revenue of $1.2 Billion Increased 10%, Compared to Third Quarter 2013 Third Quarter 2014 Reported Net Income of $166 Million, or Diluted EPS of $0.33, Increased 27%, Compared to Third Quarter 2013 Third Quarter 2014 Adjusted Net Income of $207 Million, or Adjusted Diluted EPS 1 of $0.41, Increased 20% and 21%, Respectively, Compared to Third Quarter 2013 Company Reaffirms Full-Year 2014 Adjusted Diluted EPS 1 Guidance of $1.50 - $1.54 Zoetis Inc. (NYSE:ZTS) today reported its financial results for the third quarter of 2014. The company reported revenue of $1.2 billion for the third quarter of 2014, an increase of 10% from the third quarter of 2013. Revenue reflected an operational2 increase of 10%, with foreign currency having no material impact on revenue growth this quarter. Net income for the third quarter of 2014 was $166 million, or $0.33 per diluted share, an increase of 27%, compared to the third quarter of 2013. Adjusted net income 1 for the third quarter of
...
October 2, 2014
The Board of Directors of Zoetis Inc. (NYSE:ZTS) declared a fourth quarter dividend payable to holders of the company’s common stock of $0.072 per share. The dividend is to be paid on Tuesday, Dec. 2, 2014, to holders of record on Wednesday, Nov. 5, 2014. About Zoetis Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. In 2013, the company generated annual revenue of $4.6 billion. With approximately 9,800 employees worldwide at the beginning of 2014, Zoetis has a local presence in approximately 70 countries, including 27 manufacturing facilities in 10 countries. Its products serve veterinarians, livestock producers and people who raise and care for farm and companion animals in 120
...
September 30, 2014
Zoetis Inc. (NYSE: ZTS) will host a webcast and conference call at 8:30 a.m. (EST) on Tuesday, November 4, 2014. Chief Executive Officer Juan Ramón Alaix and Executive Vice President and Chief Financial Officer Paul Herendeen will review third quarter 2014 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. Information on accessing and pre-registering for the webcast is available beginning today. A replay of the webcast will be archived and made available on November 4, 2014. About Zoetis Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported
...
August 20, 2014
Zoetis Inc. (NYSE:ZTS) will participate in the Bank of America Merrill Lynch Global Healthcare Conference on Thursday, Sept. 18, in London, UK. Juan Ramón Alaix, Chief Executive Officer of Zoetis, will represent the company and respond to questions from analysts. He is scheduled to present at 6:25 a.m. EDT (11:25 a.m. BST). Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations. A replay of the presentation will also be available. About Zoetis Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. In 2013, the company generated annual revenue of $4.6 billion. With approximately
...
August 14, 2014
Herendeen brings 16 years of experience as CFO and substantial background in health care Zoetis Inc. (NYSE:ZTS) today announced the appointment of Paul Herendeen as its new Executive Vice President and Chief Financial Officer (EVP & CFO), completing a leadership transition that began in April. Herendeen has spent the last 16 years in CFO roles at health care companies Warner Chilcott and MedPointe, building on a successful career in finance, banking and private equity partnerships. In his role at Zoetis, Herendeen will oversee the company’s Finance and Information Technology (IT) organizations and be part of the Zoetis Executive Team, reporting to CEO Juan Ramón Alaix. He will have responsibility for the financial management, planning and operations for the company’s $4.6 billion enterprise. He will also leverage his past experiences with IT to oversee the implementation of an Enterprise Resource Planning (ERP) system based on SAP, a significant undertaking to complete the company’s
...
August 13, 2014
Zoetis Inc. (NYSE:ZTS) will participate in the Morgan Stanley Global Healthcare Conference on Wednesday, Sept. 10, in New York, N.Y. Juan Ramón Alaix, Chief Executive Officer of Zoetis, will represent the company and respond to questions from analysts. He is scheduled to present at 2:05 p.m. EDT. Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations. A replay of the presentation will also be available. About Zoetis Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. In 2013, the company generated annual revenue of $4.6 billion. With approximately 9,800 employees worldwide at
...
August 5, 2014
Zoetis Inc. (NYSE:ZTS) today announced it will hold its inaugural Investor Day for financial analysts on Tuesday, Nov. 18, at the New York Stock Exchange. The event, hosted by Chief Executive Officer Juan Ramón Alaix and other members of the Zoetis executive team, will be used to provide investors with information on the company’s strategy, capabilities and value proposition, as well as the overall animal health industry. Investors and the public may access a live audio webcast of the event and presentation materials by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. Information on accessing and pre-registering for the webcast is available today. A replay of the webcast will be archived and made available on Nov. 18, 2014. About Zoetis Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures
...
August 5, 2014
Second Quarter 2014 Revenue of $1.2 Billion Increased 4%, Compared to Second Quarter 2013 Second Quarter 2014 Reported Net Income of $136 Million, or Diluted EPS of $0.27, Increased 6% and 4%, respectively, Compared to Second Quarter 2013 Second Quarter 2014 Adjusted Net Income of $189 Million, or Adjusted Diluted EPS 1 of $0.38, Increased 6% Compared to Second Quarter 2013 Company Narrows Full-Year 2014 Adjusted Diluted EPS 1 Guidance to $1.50 - $1.54 Zoetis Inc. (NYSE:ZTS) today reported its financial results for the second quarter of 2014. The company reported revenue of $1.2 billion for the second quarter of 2014, an increase of 4% from the second quarter of 2013. Revenue reflected an operational 2 increase of 6%, with foreign currency having a negative impact of 2 percentage points. Net income for the second quarter of 2014 was $136 million, or $0.27 per diluted share, an increase of 6% and 4%, respectively, compared to the second quarter of 2013. Adjusted net income1 for the
...
July 31, 2014
The Board of Directors of Zoetis Inc. (NYSE:ZTS) declared a third quarter dividend payable to holders of the company’s common stock of $0.072 per share. The dividend is to be paid on Tuesday, Sept. 2, 2014, to holders of record on Wednesday, Aug. 20, 2014. About Zoetis Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. In 2013, the company generated annual revenue of $4.6 billion. With approximately 9,800 employees worldwide at the beginning of 2014, Zoetis has a local presence in approximately 70 countries, including 28 manufacturing facilities in 11 countries. Its products serve veterinarians, livestock producers and people who raise and care for farm and companion animals in 120
...
June 30, 2014
Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (EDT) on Tuesday, August 5, 2014. Chief Executive Officer Juan Ramón Alaix and Senior Vice President of Finance Operations and Acting Chief Financial Officer Glenn David will review second quarter 2014 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. Information on accessing and pre-registering for the webcast is available beginning today. A replay of the webcast will be archived and made available on August 5, 2014. About Zoetis Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic
...
June 3, 2014
Zoetis Inc. (NYSE:ZTS) will participate in the Goldman Sachs 35 th Annual Global Healthcare Conference on Tuesday, June 10, in Rancho Palos Verdes, Calif. Juan Ramón Alaix, chief executive officer of Zoetis, will represent the company and respond to questions from analysts. He is scheduled to present at 4:20 p.m. EDT (1:20 p.m. PDT). Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations. A replay of the presentation will also be available. About Zoetis Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. In 2013, the company generated annual revenue of $4.6 billion. With
...
May 23, 2014
Zoetis Inc. (NYSE:ZTS) will participate in the William Blair 34 th Annual Growth Stock Conference on Thursday, June 12, in Chicago, Ill. Juan Ramón Alaix, chief executive officer of Zoetis, will represent the company and respond to questions from analysts. He is scheduled to present at 9:40 a.m. EDT (8:40 a.m. CDT). Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations. A replay of the presentation will also be available. About Zoetis Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. In 2013, the company generated annual revenue of $4.6 billion. With approximately 9,800
...
May 13, 2014
Zoetis Inc. (NYSE:ZTS) marked another milestone in the company’s launch as an independent public company today, conducting its first-ever Annual Meeting of Shareholders. The company, which became fully independent in June 2013 after completing its separation from Pfizer, hosted the event this morning at the Hilton Short Hills Hotel, in Short Hills, New Jersey. Zoetis Chairman Michael McCallister presided over the business portion of the meeting and shareholder voting. He was joined by Zoetis Chief Executive Officer Juan Ramón Alaix who discussed the company’s first year as an independent company, the core strengths of its business model, and its long-term value proposition for shareholders. A full replay of the meeting is available at http://investor.zoetis.com/events-presentations , along with a copy of Mr. Alaix’s prepared remarks and presentation. Preliminary results from the Annual Meeting of Shareholders indicate the following results of shareholder voting: Gregory Norden, Louise
...
May 9, 2014
Zoetis Inc. (NYSE:ZTS) will participate in the BMO Capital Markets 2014 Farm to Market Conference on Thursday, May 22, in New York, NY. Juan Ramón Alaix, chief executive officer of Zoetis, will represent the company and respond to questions from analysts. He is scheduled to present at 1:30 p.m. EDT. Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations. A replay of the presentation will also be available. About Zoetis Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. In 2013, the company generated annual revenue of $4.6 billion. With approximately 9,800 employees worldwide
...
May 6, 2014
First Quarter 2014 Revenue of $1.1 Billion Increased 1%, Compared to First Quarter 2013 First Quarter 2014 Reported Net Income of $155 Million, or Diluted EPS of $0.31, Increased 11%, Compared to First Quarter 2013 First Quarter 2014 Adjusted Net Income of $191 Million, or Adjusted Diluted EPS 1 of $0.38, Increased 7% and 6%, Respectively, Compared to First Quarter 2013 Company Reaffirms Full-Year 2014 Adjusted Diluted EPS 1 Guidance of $1.48 - $1.54 Zoetis Inc. (NYSE:ZTS) today reported its financial results for the first quarter of 2014. The company reported revenue of $1.1 billion for the first quarter of 2014, an increase of 1% from the first quarter of 2013. Revenue reflected an operational 2 increase of 4%, with foreign currency having a negative impact of 3 percentage points. Net income for the first quarter of 2014 was $155 million, or $0.31 per diluted share, an increase of 11%, compared to the first quarter of 2013. Adjusted net income1 for the first quarter of 2014 was $191
...
March 31, 2014
Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (EDT) on Tuesday, May 6, 2014. Chief Executive Officer Juan Ramón Alaix and Executive Vice President and Chief Financial Officer Rick Passov will review first quarter 2014 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. Information on accessing and pre-registering for the webcast is available beginning today. A replay of the webcast will be archived and made available on May 6, 2014. About Zoetis Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of
...
March 26, 2014
The Board of Directors of Zoetis Inc.(NYSE:ZTS) declared a second quarter dividend payable to holders of the company’s common stock of $0.072 per share. The dividend is to be paid on June 2, 2014 to holders of record on April 28, 2014. About Zoetis Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. In 2013, the company generated annual revenue of $4.6 billion. With approximately 9,800 employees worldwide at the beginning of 2014, Zoetis has a local presence in approximately 70 countries, including 28 manufacturing facilities in 11 countries. Its products serve veterinarians, livestock producers and people who raise and care for farm and companion animals in 120 countries. For more
...
March 13, 2014
Zoetis Inc. (NYSE:ZTS) will participate in the Jefferies Animal Health Summit on Thursday, March 27, at the Jefferies Conference Center in New York, NY. Juan Ramón Alaix, chief executive officer of Zoetis, will represent the company and respond to questions from analysts. He is scheduled to present at 9:30 a.m. ET. Investors and other interested parties will be able to access the presentation materials by visiting http://investor.zoetis.com/events-presentations after the presentation is delivered. About Zoetis Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. In 2013, the company generated annual revenue of $4.6 billion. With approximately 9,800 employees worldwide at the
...
February 20, 2014
Zoetis Inc. (NYSE:ZTS) today announced that the company’s 2014 Annual Meeting of Shareholders will be held on Tuesday, May 13, 2014 at 10:00 a.m. ET at the Hilton Short Hills Hotel, 41 John F. Kennedy Parkway, Short Hills, NJ 07078. Additional information regarding deadlines for shareholders’ proposals will be filed with the Securities and Exchange Commission by Zoetis on a Current Report on Form 8-K. About Zoetis Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. In 2013, the company generated annual revenue of $4.6 billion. With approximately 9,800 employees worldwide at the beginning of 2014, Zoetis has a local presence in approximately 70 countries, including 28 manufacturing
...
February 11, 2014
Fourth Quarter 2013 Revenue of $1.25 Billion Increased 7% Compared to Fourth Quarter 2012 Fourth Quarter 2013 Reported Net Income of $105 Million, or $0.21 per Diluted Share Fourth Quarter 2013 Adjusted Net Income of $180 Million, or Adjusted Diluted EPS 1 of $0.36 For Full Year 2013, Revenue of $4.56 Billion Increased 5%; Adjusted Net Income of $709 Million, or Adjusted Diluted EPS 1 of $1.42, Increased 32% and 31%, respectively Company Sets Full-Year 2014 Guidance for Revenue of $4.65 - $4.75 Billion and Adjusted Diluted EPS 1 of $1.48 - $1.54 Zoetis Inc. (NYSE:ZTS) today reported its financial results for the fourth quarter and full year 2013. The company reported revenue of $1.25 billion for the fourth quarter of 2013, an increase of 7% from the fourth quarter of 2012. Revenue reflected an operational 2 increase of 9%, with foreign currency having a negative impact of 2 percentage points. Net income for the fourth quarter of 2013 was $105 million, or $0.21 per diluted share.
...